CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead

Eldad Zacksenhaus; Jeff C Liu; Letizia Granieri; Ioulia Vorobieva; Dong-Yu Wang; Ronak Ghanbari-Azarnier; Huiqin Li; Amjad Ali; Philip E D Chung; YoungJun Ju; Zhe Jiang; Mariusz Shrestha

doi:10.1080/23723556.2018.1481814

CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead

Mol Cell Oncol. 2018 Aug 15;5(4):e1481814. doi: 10.1080/23723556.2018.1481814. eCollection 2018.

Authors

Eldad Zacksenhaus^{1

2

3}, Jeff C Liu¹, Letizia Granieri^{1

4}, Ioulia Vorobieva^{1

2}, Dong-Yu Wang¹, Ronak Ghanbari-Azarnier^{1

2}, Huiqin Li¹, Amjad Ali¹, Philip E D Chung^{1

2}, YoungJun Ju¹, Zhe Jiang¹, Mariusz Shrestha^{1

2}

Affiliations

¹ Toronto General Research Institute - University Health Network, Toronto, Ontario, Canada.
² Department of Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada.
³ Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
⁴ European Institute of Oncology, Milan, Italy.

Abstract

The dual phosphatase CDC25 has recently been identified as a target for diverse triple-negative breast cancers including RB1/PTEN/P53-deficient tumors. Moreover, CDC25 inhibitors effectively synergize with PI3K inhibitors to suppress tumor growth. We discuss these findings and the challenges that lie ahead in bringing CDC25 inhibitors to the clinic.

Keywords: CDC25 inhibitors; PTEN; RB1; Triple negative breast cancer; p53; therapy.

Grants and funding

Research in the Zacksenhaus laboratory is funded by grants from the Canadian Cancer Society, the Canadian Institute of Health Research, DoD Breast Cancer Research Program, Israel Cancer Research Fund, and the Terry Fox Research Institute.